Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-Linked hypophosphataemia: rationale and description

Maria Luisa Brandi*, Gema Ariceta, Signe Sparre Beck-Nielsen, Annemieke M. Boot, Karine Briot, Carmen de Lucas Collantes, Francesco Emma, Sandro Giannini, Dieter Haffner, Richard Keen, Elena Levtchenko, Outi Makitie, Ola Nilsson, Dirk Schnabel, Liana Tripto-Shkolnik, M. Carola Zillikens, Jonathan Liu, Alina Tudor, M. Zulf Mughal

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
11 Downloads (Pure)


Background: X-linked hypophosphataemia (XLH) is a rare, inherited, phosphate-wasting disorder that elevates fibroblast growth factor 23 (FGF23), causing renal phosphate-wasting and impaired active vitamin D (1,25(OH) 2D) synthesis. Disease characteristics include rickets, osteomalacia, odontomalacia, and short stature. Historically, treatment has been oral phosphate and 1,25(OH) 2D supplements. However, these treatments do not correct the primary pathogenic mechanism or treat all symptoms and can be associated with adverse effects. Burosumab is a recombinant human immunoglobulin G1 monoclonal antibody against FGF23, approved for treating XLH in several geographical regions, including Europe and Israel. Burosumab restores normal serum phosphate levels, minimising the clinical consequences of XLH. Safety data on long-term treatment with burosumab are lacking owing to the rarity of XLH. This post-authorisation safety study (PASS) aims to evaluate the safety outcomes in patients aged >1 year. Methods: The PASS is a 10-year retrospective and prospective cohort study utilising data from the International XLH Registry (NCT03193476), which includes standard diagnostic and monitoring practice data at participating centres. The PASS aims to evaluate frequency and severity of safety outcomes, frequency and outcomes of pregnancies in female patients, and safety outcomes in patients with mild to moderate kidney disease at baseline, in children, adolescents and adults treated with burosumab for XLH. It is expected that there will be at least 400 patients who will be administered burosumab. Results: Data collection started on 24 April 2019. The expected date of the final study report is 31 December 2028, with two interim reports. Conclusion: This PASS will provide data on the long-term safety of burosumab treatment for XLH patients and describe safety outcomes for patients receiving burosumab contrasted with those patients receiving other XLH treatments, to help inform the future management of XLH patients. The PASS will be the largest real-world safety study of burosumab. Registry identification: The International XLH Registry is registered with as NCT03193476 (, and the PASS is registered with the European Union electronic Register of Post-Authorisation Studies as EUPAS32190 (

Original languageEnglish
Number of pages13
JournalTherapeutic Advances in Chronic Disease
Early online date5 Sept 2022
Publication statusPublished - 2022

Bibliographical note

Funding Information:
The authors thank the patients/guardians who agreed to take part in the registry/PASS. Medical writing support for this manuscript was provided by Phil Long, PhD, and Edward Maguire, PhD (90TEN), funded by Kyowa Kirin International plc. The authors maintained full editorial control of the paper and provided their final approval of all content. The International XLH Registry was implemented by Kyowa Kirin International plc, and supported first by Medialis Ltd., a CRO, for the first year of the registry; then in March 2019, Kyowa Kirin International plc commissioned a new CRO, that is, IQVIA, to support the International XLH Registry, taking over CRO duties from the previous CRO. As part of the transition, Kyowa Kirin International plc updated the core documents to refer to the burosumab PASS as a sub-study embedded within the main International XLH Registry and reassigned the role of data controller from the patient to the sponsor.

Funding Information:
AB has received research grants and received honoraria as a consultant and speaker, paid to her institution, from Kyowa Kirin and Ultragenyx. CLC has received honoraria as a consultant for Kyowa Kirin. MCZ reports that her institution has received a research grant from Kyowa Kirin. DH has received a research grant or honoraria as a consultant and speaker from Amgen, Chiesi and Kyowa Kirin. DS has received honoraria as a consultant from BioMarin, Kyowa Kirin, Novo Nordisk and Sandoz. EL has received honoraria as a consultant from Advicenne, Chiesi, Kyowa Kirin, Novartis and Recordati. FE declares competing interests with Avrobio, Chiesi, Kyowa Kirin, Otsuka and Recordati Rare Diseases. GA has received personal fees and non-financial support from Advicenne, Alexion, Kyowa Kirin, Recordati Rare Diseases and received personal fees from Alnylam and Dicerna, and received personal fees and other from Chiesi. KB has received honoraria as a consultant from Amgen, Kyowa Kirin, Theramex and UCB. LTS has received honoraria as a consultant from Amgen and Kyowa Kirin. MB has received research grants or honoraria as a consultant or speaker from Abiogen, Alexion, Amgen, Bruno Farmaceutici, Calilytix, Echolight, Eli Lilly, Kyowa Kirin, SPA, Theramex and UCB. ON has received honoraria as a consultant from BioMarin and Kyowa Kirin. OM has received honoraria as a consultant from BridgeBio, Kyowa Kirin and Ultragenyx. RK has received honoraria as a consultant or for advisory boards from Kyowa Kirin. SBN and ZM have received honoraria as a consultant or speaker from Inozyme Pharma and Kyowa Kirin. JL and AT are employees of Kyowa Kirin International plc. SG declares no conflict of interests.

Publisher Copyright:
© The Author(s), 2022.


Dive into the research topics of 'Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-Linked hypophosphataemia: rationale and description'. Together they form a unique fingerprint.

Cite this